Tarlatamab has become part of the standard of care (SOC) in the second-line setting and beyond for extensive-stage small cell lung cancer (ES-SCLC). In the phase Ib DeLLphi-303 trial, tarlatamab in combination with a PD-L1 inhibitor demonstrated encouraging antitumor activity as a first-line maintenance therapy for patients with ES-SCLC, achieving a median overall survival (OS) of 25.3 months.

New data from the DeLLphi-305 trial further support tarlatamab as first-line maintenance therapy in ES-SCLC, demonstrating significant improvements in OS, progression-free survival (PFS), and objective response rate (ORR). This randomized phase III trial evaluated tarlatamab plus durvalumab versus durvalumab monotherapy as first-line maintenance therapy after initial induction with platinum-etoposide plus durvalumab.
Jacob Sands, MD, of the Dana-Farber Cancer Institute, Boston, reported results from a prespecified interim analysis of the data at the 2026 European Society for Medical Oncology Congress in Madrid.
DeLLphi-305 randomly assigned 563 patients in a 1:1 ratio to receive tarlatamab (10 mg once every two weeks [Q2W]) plus durvalumab (1,500 mg once every four weeks [Q4W]) or durvalumab monotherapy (1,500 mg Q4W) until disease progression or unacceptable toxicity.
“DeLLphi-305 has demonstrated unprecedented outcomes in both median overall survival and median progression-free survival, along with durability for a substantial subset of patients, all with a toxicity profile that appears manageable.”
– Jacob Sands, MD
Baseline characteristics were similar across both cohorts. Brain metastases were present in nearly 20% of patients in each group, and nearly one-third of patients in both cohorts had liver metastases.
The primary endpoint was OS. Key secondary endpoints included PFS, ORR, duration of response (DoR), and safety.
Tarlatamab in combination with durvalumab significantly improved OS compared with durvalumab alone as first-line maintenance therapy.
“The tarlatamab plus durvalumab arm had a median OS of 21.1 months. This is compared to durvalumab at 12.7 months, representing a hazard ratio (HR) of 0.42,” Dr. Sands said. “The median follow-up is about 16 months.” Dr. Sands noted that this is not the final median OS data.
He also highlighted that this OS benefit appeared to be consistent across all subgroups. This includes groups that had or did not have baseline brain metastases, liver metastases, and whether they had an initial response to induction therapy or stable disease.
Tarlatamab plus durvalumab also exhibited a significant improvement in PFS versus durvalumab monotherapy (median PFS: 7.4 months vs. 1.9 months; HR 0.34). PFS favored tarlatamab in combination with durvalumab across prespecified subgroups.
“We do this work not to improve everybody’s survival by a few months, but to improve it by years. From this data, we see at the one-year time point, 38% of patients are progression-free in the tarlatamab plus durvalumab arm, compared with the 10% in the durvalumab arm,” Dr. Sands said.
The combination of tarlatamab with durvalumab also demonstrated notable improvements in ORR versus durvalumab alone (ORR: 26.4% with tarlatamab plus durvalumab vs. 4.1% with durvalumab alone).
“When looking at response rate, I would like to acknowledge that I don’t think there’s a lot of validity to evaluating the response of durvalumab maintenance after patients have been getting platinum etoposide plus durvalumab,” Dr. Sands said. “This is an endpoint more so to look at the inclusion of tarlatamab and what is that doing, and how meaningful is that? And, in subsets of patients in the future, how can we anticipate what’s going to happen for them?”
Regarding DoR, in patients who responded to tarlatamab combined with durvalumab in the maintenance setting, 52% maintained that response at the one-year mark. As of the July 7, 2026, data cut-off date, 43.6% of patients remained on treatment with tarlatamab plus durvalumab, compared with 11.4% in the durvalumab-only cohort.
The safety profile was fairly similar between the two treatment groups. More patients in the tarlatamab-durvalumab arm experienced any-grade treatment-related adverse events (TRAEs) (95%) than in the durvalumab-only group (52.2%). Treatment with tarlatamab plus durvalumab was associated with a low frequency of TRAEs leading to treatment discontinuation (3.2%), comparable to the durvalumab-only cohort (3.6%).
Additionally, there were no treatment-related fatalities reported in the tarlatamab-durvalumab arm versus two cases among patients who received durvalumab monotherapy.
Cytokine release syndrome (CRS) events occurred in nearly half of patients treated with tarlatamab plus durvalumab; however, most were grade 1, Dr. Sands said. Additionally, immune effector cell-associated neurotoxicity syndrome (ICANS) events were noted in three patients treated with tarlatamab plus durvalumab.
“DeLLphi-305 has demonstrated unprecedented outcomes in both median OS and median PFS, along with durability for a substantial subset of patients, all with a toxicity profile that appears manageable,” Dr. Sands said. “With all of this together, this highlights tarlatamab plus durvalumab in the first-line maintenance setting as a new SOC in the treatment of ES-SCLC.”
